| Patent Number |
Title Of Patent |
Date Issued |
| RE40558 |
Therapeutic uses of di-aryl acid derivatives |
October 28, 2008 |
| The use of diaryl acid derivatives of formula (I) ##STR00001## or pharmaceutically acceptable salts, N-oxides, hydrates or solvates thereof, wherein the variables shown are defined in the disclosure, and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR li |
| 7453009 |
Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use |
November 18, 2008 |
| Disclosed are novel compound of formula I, ##STR00001## As defined herein and their use as pharmaceutically active compounds for reducing blood glucose, and/or treating one or more of type II diabetes, disturbances of lipid and carbohydrate metabolism, arteriosclerotic manifestations, a |
| 7453000 |
Substituted oxazolobenzoisothiazole dioxide derivatives method for production and use thereof |
November 18, 2008 |
| The invention relates to compounds of formula (I), where the groups have the meanings set forth herein and the physiologically-acceptable salts thereof. The compounds are suitable as medicaments for lowering blood sugar levels and for prevention and treatment of diabetes. ##STR00001## |
| 7452860 |
Zinc-free and low-zinc insulin preparations having improved stability |
November 18, 2008 |
| The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent |
| 7449594 |
Process for preparing 4-pentafluorosulfanylbenzoylguanidines |
November 11, 2008 |
| A process for preparing 4-pentafluorosulfanylbenzoylguanidines of formula I ##STR00001## wherein R1 to R4 have the meanings indicated in the specification. The compounds of formula I are NEH1 inhibitors and can be employed, for example, for the treatment of cardiovascular disorders. |
| 7449560 |
Phosophoinositoglycan binding proteins |
November 11, 2008 |
| The invention refers to a protein from plasma membrane of adipocytes. The protein has specific binding affinity to phosphoinositoylglycans. It regulates glucose uptake by circumventing the insulin signaling cascade. |
| 7446225 |
Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, thei |
November 4, 2008 |
| The invention relates to pentafluorosulfanylphenyl-substituted benzoylguanidines of the formula I: ##STR00001## and a process for preparing a compound of the formula I and/or the pharmaceutically acceptable salts thereof. |
| 7445925 |
Aequorin as a reporter gene in yeast |
November 4, 2008 |
| A yeast transduction pathway-inducible expression cassette for aequorin and yeast cells containing the expression cassette are disclosed, as well as methods of using the yeast cells in screening assays. |
| 7442717 |
Substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnos |
October 28, 2008 |
| Novel substituted 2-aminoimidazoles of formula I, process for their preparation, their use as medicament or diagnostic aid, and medicament containing them. The compounds of this type are useful in the prevention or treatment of various disorders and can be employed inter alia for ren |
| 7435868 |
Screening assay based on the forkhead transcription factor-dependent sod-3 promoter |
October 14, 2008 |
| The invention relates to the identification and use of the DAF-2/IR responsive sod-3 promoter. Transgenic C. elegans containing sod-3 reporter gene constructs are described which are useful for, among other things, the identification of genes or compounds capable of modulating the DA |
| 7435747 |
Guanidine and amidine derivatives as factor Xa inhibitors |
October 14, 2008 |
| The present invention relates to compounds of the formula I, ##STR00001## in which R.sub.0; Q; X; Q', D, R.sub.10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effe |
| 7435727 |
Method for isolating an intestinal cholesterol binding protein |
October 14, 2008 |
| The invention describes a method for isolating an intestinal protein which is able to bind cholesterol and/or cholesterol uptake inhibitors. Methods of identifying inhibitors of cholesterol uptake and related pharmaceuticals and methods of treatment also are described. |
| 7429581 |
Pyrazole-derivatives as factor Xa inhibitors |
September 30, 2008 |
| The present invention is directed to a compound of formula I, ##STR00001## in which R.sup.0; R.sup.1; R.sup.2; R.sup.3; R.sup.4; Q; V, G and M have the meanings indicated below. The compound of formula I is a pharmacologically active compound. It exhibits a strong anti-thrombotic ef |
| 7429449 |
Potassium channel mutants of the yeast Saccharomyces cerevisiae and their use for screening euk |
September 30, 2008 |
| The invention relates to processes for identifying inhibitors and activators of eukaryotic potassium channels, in which a mutated S. cerevisiae cell is used whose endogenous potassium channels TRK1, TRK2 and TOK1 are not expressed functionally, but which expresses heterologously a eu |
| 7402674 |
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their |
July 22, 2008 |
| 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicamentsThe invention relates to 7-phenylamino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives th |
| 7402601 |
Pharmaceuticals for the treatment of rejection reactions in organ transplantations |
July 22, 2008 |
| The use of compound 1 and/or 2 of the formulae ##STR00001## and of physiologically tolerable salts of compound 2 for the treatment of rejection reactions of the organ recipient to the transplanted organ is described. |
| 7399900 |
Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular |
July 15, 2008 |
| The invention relates to nematodes as model organisms for the investigation of neurodegenerative diseases in particular. Parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of |
| 7399777 |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
July 15, 2008 |
| Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, ##STR00001## in which the radicals are as defined, and their physiologically acceptable salts and processes for |
| 7399770 |
Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors |
July 15, 2008 |
| The invention is directed to a compound of the formula I ##STR00001## wherein the variables are as defined herein, or a stereoisomeric form thereof, mixture of stereoisomeric forms, in any ratio, or a salt thereof.Another aspect of the present invention is directed to a pharmaceutica |
| 7390814 |
Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their prepar |
June 24, 2008 |
| Substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicamentsThe invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiological |
| 7390790 |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising the |
June 24, 2008 |
| One embodiment of the invention relates to compounds of the formula I, ##STR00001## in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes |
| 7388004 |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprisi |
June 17, 2008 |
| One embodiment of the invention relates to compounds of the formula I: ##STR00001## in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of the compounds of formula I, to proces |
| 7381841 |
Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their |
June 3, 2008 |
| Pentafluorosulfany0lphenyl-substituted benzoylguanidines, process for their preparation, theie use as medicament or diagnostic aed, and medicament comprising them Pentafluorosulfany0lphenyl-substituted benzoylguanidines of the formulae I and II ##STR00001## in which R1, R1', R2, R2' |
| 7378440 |
Substituted benzoylureido-o-benzoylamides, process for their preparation and their use |
May 27, 2008 |
| The invention relates to substituted benzoylureido-o-benzoylamides and to their physiologically tolerated salts and physiologically functional derivatives.The invention relates to compounds of the formula I ##STR00001## in which the radicals have the stated meanings, and to the phys |
| 7378252 |
Process for identifying modulators of G-protein-coupled receptors |
May 27, 2008 |
| The invention relates to a widely applicable process for identifying chemical compounds, which modulate G-protein-coupled receptors, by means of novel hybrid G-proteins with broad receptor specificity and very high expression and also to chemical compounds which can be identified by such |
| 7375138 |
Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments |
May 20, 2008 |
| Pentafluorosulfanylbenzoylguanidines of the formula I and II ##STR00001## in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the t |
| 7368469 |
Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
May 6, 2008 |
| Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular eve |
| 7365088 |
Indazole-derivatives as factor Xa inhibitors |
April 29, 2008 |
| The present invention relates to a compound of the formula I ##STR00001## wherein J.sub.1, J.sub.2, R.sup.0, R.sup.1, R.sup.2, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic eff |
| 7365084 |
Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as |
April 29, 2008 |
| Provided herein are cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals. |
| 7364887 |
Use of PAK inhibitor for the treatment of a joint disease |
April 29, 2008 |
| The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament f |
| 7358268 |
Imidazole derivatives as factor Xa inhibitors |
April 15, 2008 |
| This invention is directed to the compound of formula (I) which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as in inhibiting the formation of thrombi |
| 7351703 |
Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators |
April 1, 2008 |
| The present invention relates to compounds of the formula I ##STR00001## in which A.sup.1, A.sup.2, R.sup.2 and R.sup.3 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases, for example of cardiovasc |
| 7348336 |
Substituted .beta.-carbolines |
March 25, 2008 |
| The subject matter of the present invention is directed to novel substituted .beta.-carbolines, and specifically compounds of the formula I, ##STR00001## which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased |
| 7348155 |
Method for identifying compounds for treating aging processes in the coronary circulatory system |
March 25, 2008 |
| The invention relates to a method for identifying a compound which modifies the activity of the urotensin II receptor, with genes or gene products which are involved in the structure, formation or breakdown of the extracellular matrix being influenced. |
| 7342029 |
Substituted indoles |
March 11, 2008 |
| Compounds of the formula I ##STR00001## are suitable for preparing pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF.kappa.B is involved. |
| 7338956 |
Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
March 4, 2008 |
| The present invention relates to acylamino-substituted heteroaromatic compounds of formula I, ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 and X are as defined herein, to pharmaceutical compositions comprising such compounds, to methods for the stimulation of |
| 7335671 |
Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their |
February 26, 2008 |
| Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticalsThe invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives |
| 7332608 |
Anthranilamides and methods of their use |
February 19, 2008 |
| The present invention is related to a process for preparing anthranilamides of formula I, ##STR00001## in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds |
| 7332607 |
Processes for the preparation of (R)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4 |
February 19, 2008 |
| The present invention provides various processes for the preparation of (R)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidin- emethanol. These processes may be characterized by the following scheme: ##STR00001## |
| 7326789 |
Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and p |
February 5, 2008 |
| The present invention relates to compounds of the formula I ##STR00001## wherein A.sup.1, A.sup.2, R.sup.1, R.sup.2, R.sup.3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiov |
| 7319108 |
Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
January 15, 2008 |
| The invention relates to substituted aryl-substituted heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof, to process for their preparation and to their use as medicaments.Compounds of the Formula I ##STR00001## in which the rad |
| 7319024 |
C. elegans p21-activated kinase (PAK) gene and associated loss-of-function phenotypes that facil |
January 15, 2008 |
| The invention refers to a novel C. elegans p21-activated kinase gene, the pak-3 gene, and associated loss-of-function phenotypes. These phenotypes can be used to elucidate PAK signaling pathways in C. elegans and to screen compounds that modulate PAK signaling. |
| 7317124 |
Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as va |
January 8, 2008 |
| Pentafluorosulfanyl-benzenes according to Formula (I): ##STR00001## a process for their preparation and their use as valuable synthetic intermediates for preparing, for example, medicaments, diagnostic aids, liquid crystals, polymers, pesticides, herbicides, fungicides, nematicides, |
| 7317033 |
Substituted thiophenes: compositions, processes of making, and uses in disease treatment and dia |
January 8, 2008 |
| Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic agent. The substituted thiophene derivatives have the following backbone structure: ##STR00001## Medicaments comprising compounds of this type are of use for preventing or treating various |
| 7317027 |
Azaindole-derivatives as factor Xa inhibitors |
January 8, 2008 |
| The present invention relates to compounds of the formula I ##STR00001## wherein R.sup.0, R.sup.1, R.sup.2, R.sup.3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are |
| 7314753 |
Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins i |
January 1, 2008 |
| The invention relates to the cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli. In particular, antibody fragment fusion molecules having an antibody moiety which is directed against tumors and an enzyme moiety which cleaves a n |
| 7309701 |
Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them |
December 18, 2007 |
| The present invention relates to novel pyridazinone derivatives of the general formula (I) ##STR00001## wherein A is A1 or A2; ##STR00002## R is unsubstituted or at least monosubstituted C.sub.1-C.sub.10-alkyl, aryl, aryl-(C.sub.1-C.sub.10-alkyl)-, heteroaryl, heteroaryl-(C.s |
| 7309579 |
Method for screening for activators of soluble guanylate cyclase having oxidized heme iron |
December 18, 2007 |
| The invention relates to methods for detecting a soluble guanylate cyclase whose heme iron is in the trivalent oxidation state, and to methods for finding chemical substances which stimulate the activity of a soluble guanylate cyclase when the heme iron of at least part of this soluble |
| 7300764 |
Method for identifying agonists and antagonists of the GPR45-like/GPR63 receptor |
November 27, 2007 |
| Embodiments of the present invention relate to methods for identifying compounds which modify the activity of the G protein-coupled receptor GPR45 like/GPR63, compositions useful for this method, and compounds identified by it. |
| 7288528 |
Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereo |
October 30, 2007 |
| Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof.The invention relates to substituted aromatic fluoroglycoside derivatives of the formula I ##STR00001## in which the radicals have the stated meanings, and their physiologically t |
